Synthetic Miniproteins Enter the Fight Against MYC-Driven Cancers
The transcription factor MYC is a master regulator implicated in the majority of human cancers. Despite its central role, MYC has long been considered "undruggable" by small molecules, lacking binding pockets and featuring disordered regions. While larger biomolecules could potentially disrupt MYC function, their inability to penetrate cells has limited their therapeutic application.
Now, the Pomplun lab has developed DuoMYC, a synthetic miniprotein capable of entering cells and directly inhibiting MYC activity. This innovative approach overcomes the challenges of MYC’s undruggable nature, opening the door to new therapeutic possibilities.
Curious how DuoMYC works? Read the full paper by B. Ellenbroek, J.P Kahler et al. for details!
